Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical to launch the novel gastrointestinal drug Vonoprazan in India. The drug, which addresses common conditions such as GERD and peptic ulcers, will be marketed under Dr. Reddy’s trademark VONO™ in two strengths. This move underscores Dr. Reddy’s commitment to expanding its portfolio and providing innovative treatments to meet the health needs of patients in India.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
